ATE556998T1 - Salicylamidderivate als nikotinische alpha-7- modulatoren - Google Patents

Salicylamidderivate als nikotinische alpha-7- modulatoren

Info

Publication number
ATE556998T1
ATE556998T1 AT09781410T AT09781410T ATE556998T1 AT E556998 T1 ATE556998 T1 AT E556998T1 AT 09781410 T AT09781410 T AT 09781410T AT 09781410 T AT09781410 T AT 09781410T AT E556998 T1 ATE556998 T1 AT E556998T1
Authority
AT
Austria
Prior art keywords
modulators
nicotinic alpha
salicylamide derivatives
salicylamide
derivatives
Prior art date
Application number
AT09781410T
Other languages
English (en)
Inventor
Todd Richard Elworthy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE556998T1 publication Critical patent/ATE556998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/62—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AT09781410T 2008-08-12 2009-08-03 Salicylamidderivate als nikotinische alpha-7- modulatoren ATE556998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8810808P 2008-08-12 2008-08-12
PCT/EP2009/060016 WO2010018095A1 (en) 2008-08-12 2009-08-03 Salicylamide derivatives as nicotinic alpha 7 modulators

Publications (1)

Publication Number Publication Date
ATE556998T1 true ATE556998T1 (de) 2012-05-15

Family

ID=41055425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09781410T ATE556998T1 (de) 2008-08-12 2009-08-03 Salicylamidderivate als nikotinische alpha-7- modulatoren

Country Status (13)

Country Link
US (1) US8198332B2 (de)
EP (1) EP2323971B1 (de)
JP (1) JP5341190B2 (de)
KR (1) KR101333401B1 (de)
CN (1) CN102119142B (de)
AT (1) ATE556998T1 (de)
AU (1) AU2009281243A1 (de)
BR (1) BRPI0917803A2 (de)
CA (1) CA2728451C (de)
ES (1) ES2386760T3 (de)
IL (1) IL209732A0 (de)
MX (1) MX2011000841A (de)
WO (1) WO2010018095A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191799A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof
GEAP202014908A (en) 2016-03-22 2020-03-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05239005A (ja) * 1992-02-28 1993-09-17 Kitsuen Kagaku Kenkyu Zaidan Ｎ−（２−アミノエチル）ベンズアミド類およびその新規中間体
BRPI0517494A (pt) * 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
PE20080311A1 (es) * 2006-05-30 2008-05-23 Glaxo Group Ltd Derivados de oxadiazol como agentes afines a receptores nicotinicos

Also Published As

Publication number Publication date
CA2728451A1 (en) 2010-02-18
IL209732A0 (en) 2011-02-28
US8198332B2 (en) 2012-06-12
US20100041763A1 (en) 2010-02-18
EP2323971B1 (de) 2012-05-09
MX2011000841A (es) 2011-02-25
CN102119142B (zh) 2013-12-04
CA2728451C (en) 2013-09-24
ES2386760T3 (es) 2012-08-29
CN102119142A (zh) 2011-07-06
AU2009281243A1 (en) 2010-02-18
KR20110028652A (ko) 2011-03-21
JP5341190B2 (ja) 2013-11-13
BRPI0917803A2 (pt) 2019-09-03
WO2010018095A1 (en) 2010-02-18
EP2323971A1 (de) 2011-05-25
JP2011530560A (ja) 2011-12-22
KR101333401B1 (ko) 2013-11-28

Similar Documents

Publication Publication Date Title
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MY169043A (en) New dihydroquinoline-2-one derivatives
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
EA201170772A1 (ru) Органические соединения
MY151986A (en) Adamantyl diamide derivatives and uses of same
MA32508B1 (fr) Composes organiques
NO20083630L (no) Nye pyridinderivater
DK2074120T3 (da) Tropan-forbindelser
MY169267A (en) New aryl-quinoline derivatives
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MX2012008141A (es) Compuestos y metodos.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
JO2673B1 (en) New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
ATE528290T1 (de) Spiroindolinon-derivate
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
WO2014062838A3 (en) Pkm2 modulators and methods for their use
EA201290229A1 (ru) Производные спиролактама и их применение
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу